Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease.

ABSTRACT:

Introduction

Alzheimer's disease (AD) is a chronic and progressive neurodegenerative disease that places a substantial burden on patients and caregivers. Aducanumab is the first AD therapy approved by the US Food and Drug Administration to reduce a defining pathophysiological feature of the disease, brain amyloid plaques. In the phase 3 clinical trial EMERGE (NCT02484547), aducanumab reduced clinical decline in patients with mild cognitive impairment (MCI) due to AD and mild AD dementia and confirmed amyloid pathology.

Methods

We used a Markov modeling approach to predict the long-term clinical benefits of aducanumab for patients with early AD based on EMERGE efficacy data. In the model, patients could transition between AD severity levels (MCI due to AD; mild, moderate, and

SUBMITTER: Herring WL 

PROVIDER: S-EPMC8571451 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature